百时美施贵宝 (BMY.US)周二表示，美国食品药品管理局 (FDA)已批准其重磅PD-1抑制剂Opdivo (nivolumab)联合CTLA-4靶向抗体Yervoy (ipilimumab)用于治疗微卫星高度不稳定 (MSI-H)或错配修复缺陷 (dMMR)表型的转移性结直肠癌 (mCRC)成人和儿童患者。

许多患者对于结直肠癌的治疗感到茫然，而Opdivo与Yervoy的联合疗法为他们带来了新的曙光。作为一种PD-1免疫检查点抑制剂，Opdivo能够帮助恢复体内抗肿瘤的免疫反应，利用自身的免疫系统来打击癌细胞。而Yervoy则通过靶向抑制CTLA-4增强T细胞活性，从而提升肿瘤杀伤能力。这种组合实现了充分的协同作用，使得患者在面对病魔时，能拥有更强的战斗力。

The FDA has approved Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for patients with a particular form of ...

在此背景下，台湾大学医院的研究人员挺身而出，开展了一项意义重大的研究。他们尝试采用聚乙二醇化干扰素 α-2b（ropeginterferon alfa-2b，ropeg）与抗程序性死亡受体 1（programmed cell death 1，PD-1）治疗药物纳武利尤单抗（nivolumab）序贯联合作为乙肝相关肝癌术后辅助治疗的方案，并进行了 Ⅰ ...

为评估 nivolumab 用于法国成人高危复发肌层浸润性尿路上皮癌（MIUC-HR）且肿瘤细胞 PD-L1 ≥1% 患者根治术后辅助治疗的成本效益，研究人员构建四状态半 Markov 模型对比其与监测策略，结果显示 nivolumab 更具成本效益，为医疗决策提供依据。 在癌症治疗的漫漫征途 ...

During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...

An award-winning pathologist who devoted his life to melanoma research became the first person to receive a novel ...

ICI-based combinations are the preferred first-line therapy due to their proven superiority over TKI monotherapy, many patients were not receiving them,” the researchers wrote.

As proof of concept of these novel pathways, the Company completed a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC) with CM24 as a combination therapy with the anti-PD-1 ...

whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. OPDIVO ® (nivolumab), in combination with YERVOY® (ipilimumab ...

Adding nivolumab to neoadjuvant chemotherapy significantly improves response rates in high-risk early-stage ER+/HER2− breast ...